Innovent Biologics company profile

1801 · HKEX · HKD

Compare Innovent Biologics
$80.10Change from previous close: −6.26%Absolute change: −$5.35

Close · November 20, 2026

Company profile

Innovent Biologics has 8,754 employees and is headquartered in Suzhou, China.

TYVYT, BYVASDA, SULINNO and Cyramza are among the brands through which Innovent Biologics, Inc. is best known, alongside Retsevmo and Jaypirca. The company works on antibody and protein medicines and takes them from discovery through manufacturing to sale, with therapies aimed at cancer, eye diseases, autoimmune conditions, heart disease and metabolic disorders. Besides its own portfolio, it distributes pharmaceutical products and provides consulting and research and development services. Its activity spans mainland China, the United States and Europe, as well as other international markets.

In the fiscal year ended December 2025, Innovent recorded revenue of CNY 13.0 billion, up 38.4% from the previous year, and net income of CNY 813.6 million. The company had 8,754 employees. It was founded in 2011 and is headquartered in Suzhou.

Company facts

Industry
Biotechnology
Headquarters
168 Dongping Street, 215123, Suzhou
Employees
8,754
Chief executive
De-Chao Yu
Founded
2011
Fiscal year
January - December
Listing
1801 · HKEX
Indices
Hang Seng
Currency
HKD
ISIN
KYG4818G1010

Innovent Biologics and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Innovent Biologics1801Hong Kong SAR China$17.82B8,7547.4%105.4
WuXi Biologics (Cayman)2269Hong Kong SAR China$21.51B14,70532.4%30.8
Sichuan Kelun-Biotech Biopharmaceutical6990Hong Kong SAR China$12.15B2,300-0.2%—
Sino Biopharmaceutical1177Hong Kong SAR China$11.65B22,83828.2%34.2
Pharmaron Beijing300759China$10.59B25,08814.0%39.3
ALTEOGEN196170South Korea$9.05B18147.2%97.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Innovent Biologics with its competitors